Champlain Investment Partners
ATRC icon

Champlain Investment Partners’s AtriCure ATRC Stock Holding History

Champlain Investment Partners’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.2M Sell
466,167
-472,400
-50% -$21.3M 0.9% 39
2026
Q2 		$26.3M Sell
938,567
-32,544
-3% -$916K 0.67% 66
2026
Q1 		$27.7M Sell
971,111
-202,494
-17% -$6.91M 0.35% 96
2025
Q4 		$46.4M Sell
1,173,605
-804,608
-41% -$29.5M 0.47% 85
2025
Q3 		$69.7M Sell
1,978,213
-38,541
-2% -$1.33M 0.53% 81
2025
Q2 		$66.1M Sell
2,016,754
-121,209
-6% -$3.94M 0.46% 93
2025
Q1 		$69M Sell
2,137,963
-390,651
-15% -$14.5M 0.5% 85
2024
Q4 		$77.3M Sell
2,528,614
-262,144
-9% -$8.43M 0.49% 88
2024
Q3 		$78.3M Buy
2,790,758
+115,813
+4% +$2.85M 0.47% 86
2024
Q2 		$60.9M Sell
2,674,945
-6,055
-0.2% -$140K 0.37% 98
2024
Q1 		$81.6M Buy
2,681,000
+575,605
+27% +$19.3M 0.47% 87
2023
Q4 		$75.1M Buy
2,105,395
+253,855
+14% +$9.44M 0.45% 89
2023
Q3 		$81.1M Buy
1,851,540
+41,155
+2% +$2.01M 0.53% 82
2023
Q2 		$89.4M Sell
1,810,385
-81,710
-4% -$3.77M 0.55% 78
2023
Q1 		$78.4M Sell
1,892,095
-47,645
-2% -$1.98M 0.49% 86
2022
Q4 		$86.1M Sell
1,939,740
-71,000
-4% -$2.97M 0.55% 80
2022
Q3 		$78.6M Buy
2,010,740
+391,760
+24% +$17.9M 0.54% 82
2022
Q2 		$66.2M Buy
1,618,980
+343,160
+27% +$16.3M 0.43% 95
2022
Q1 		$83.8M Buy
1,275,820
+57,270
+5% +$3.71M 0.43% 91
2021
Q4 		$84.7M Sell
1,218,550
-1,970
-0.2% -$143K 0.38% 103
2021
Q3 		$84.9M Sell
1,220,520
-340,715
-22% -$26.2M 0.41% 99
2021
Q2 		$124M Sell
1,561,235
-613,905
-28% -$44.6M 0.59% 76
2021
Q1 		$143M Buy
2,175,140
+39,560
+2% +$2.44M 0.74% 59
2020
Q4 		$119M Buy
2,135,580
+66,160
+3% +$2.86M 0.68% 64
2020
Q3 		$82.6M Buy
2,069,420
+410,185
+25% +$17.4M 0.56% 69
2020
Q2 		$74.6M Sell
1,659,235
-33,990
-2% -$1.48M 0.54% 74
2020
Q1 		$56.9M Buy
1,693,225
+443,585
+35% +$15.9M 0.51% 77
2019
Q4 		$40.6M Buy
1,249,640
+574,205
+85% +$16.3M 0.3% 104
2019
Q3 		$16.8M Buy
+675,435
New +$19.3M 0.14% 112

Other funds holding ATRC

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return

Champlain Investment Partners's ATRC Position: Q3 2026 in Review

Champlain Investment Partners reduced its AtriCure (ATRC) stake by 50% in Q3 2026, selling an estimated $21.3M and leaving 466,167 shares worth $26.2M. The position accounts for 0.9% of the portfolio, ranked #39.

Champlain Investment Partners first reported a position in ATRC in Q3 2019 and has held it in 29 quarters since. The position peaked at $143M in Q1 2021. 183 funds tracked by Wall St. Rank hold ATRC as of Q3 2026.

  • Champlain Investment Partners held 466,167 shares of AtriCure worth $26.2M as of Q3 2026.
  • Champlain Investment Partners sold 472,400 AtriCure shares in Q3 2026, an estimated $21.3M.
  • AtriCure made up 0.9% of Champlain Investment Partners's portfolio in Q3 2026, its #39 holding.
  • Champlain Investment Partners first reported a position in AtriCure in Q3 2019 and has held it in 29 quarters since.
  • Champlain Investment Partners's AtriCure position peaked at $143M in Q1 2021.
  • 183 funds tracked by Wall St. Rank held AtriCure as of Q3 2026.

Based on Champlain Investment Partners's 13F filing for Q3 2026, filed 12 Nov 2026.